La información proporcionada en EL7.AI es solo con fines educativos e informativos y no constituye asesoramiento financiero.

Última horastocks

Cingulate Inc Shares Surge Following Key Patent Approval for ADHD Treatment

Detectado por primera vez: Mar 16, 2026, 5:47 PM

Última actualización: 10 days ago

9 artículos·9 historias

Instrumentos afectados

CING

Resumen del evento

On March 16, the US Patent and Trademark Office (USPTO) approved a key patent application for Cingulate Inc's ADHD treatment. The patent protects the proprietary technology behind CTx-1301, the company's lead ADHD drug candidate. Following the announcement, Cingulate Inc shares surged in Monday morning trading.

Línea de tiempo

Sarepta Therapeutics Stock Surges on Positive siRNA Clinical Trial Results

Mar 25, 2026, 3:52 PMImpact: 7

Ciena Shares Surge as Analyst Upgrades Highlight Oracle Data Center Synergy

Mar 23, 2026, 10:31 PMImpact: 6

Sharp 8% Drop in Oil Prices Boosts Carvana Stock Performance

Mar 23, 2026, 8:04 PMImpact: 7

Planet Labs Shares Surge 15% on Record Earnings and AI-Driven Growth Outlook

Mar 20, 2026, 9:01 AMImpact: 6

Cingulate Inc Shares Surge Following Key Patent Approval for ADHD Treatment

Mar 16, 2026, 5:47 PMImpact: 7